Filing Flows › Comparisons › ARVN vs MREO
Arvinas vs Mereo BioPharma Group: ARVN and MREO compared
Arvinas is the larger company: $500K of revenue in its latest quarter (Q3 2026) against $500K for Mereo BioPharma Group (Q2 2025).
Where the money goes: ARVN and MREO
Arvinas (ARVN) · Q3 2026
Arvinas, Q3 2026: revenue $500K (-99% year over year), net loss $53.9M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
Mereo BioPharma Group (MREO) · Q2 2025
Mereo BioPharma Group, Q2 2025: revenue $500K, net loss $14.6M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
| Arvinas (ARVN) | Mereo BioPharma Group (MREO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2025 |
| Revenue | $500K | $500K |
| Revenue growth, Y/Y | -99% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$53.9M | −$14.6M |
| Operating cash flow | −$10.4M | −$7.7M |
Questions
Which is bigger, Arvinas or Mereo BioPharma Group?
Arvinas is the larger company: $500K of revenue in its latest quarter (Q3 2026) against $500K for Mereo BioPharma Group (Q2 2025).
More: Arvinas earnings · how Arvinas makes money · Mereo BioPharma Group earnings · how Mereo BioPharma Group makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Aug 12, 2025). Fiscal quarters can end on different dates. Not investment advice.